Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Lotte M. Knapen"'
Autor:
A.O.J. de Fallois, A.J. van de Wouw, Sander Croes, M.W. Dercksen, Vivianne C. G. Tjan-Heijnen, Dorien J.A. Lobbezoo, Lotte M. Knapen, M. de Boer, Sandra M. E. Geurts, Manon J. Pepels, F.W.P.J. van den Berkmortel, Khava I.E. Ibragimova, Birgit E.P.J. Vriens
Publikováno v:
Breast, 44, 46-51. Churchill Livingstone
Purpose: We aimed to assess the implementation and effectiveness of exemestane plus everolimus treatment per hospital type in real-life, shortly after approval of everolimus.Methods: Advanced breast cancer patients treated with exemestane plus everol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895e65337e369f01c0a36fcd0cccbbb3
https://doi.org/10.1016/j.breast.2019.01.001
https://doi.org/10.1016/j.breast.2019.01.001
Autor:
Sander Croes, Y. M. de Beer, Roger J. M. Brüggemann, Lotte M. Knapen, Annelieke E.C.A.B. Willemsen, N. P. van Erp, C.M.L. van Herpen
Publikováno v:
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, 74, 465-471
European Journal of Clinical Pharmacology, 74(4), 465-471. Springer
European Journal of Clinical Pharmacology, 74, 4, pp. 465-471
European Journal of Clinical Pharmacology, 74, 465-471
European Journal of Clinical Pharmacology, 74(4), 465-471. Springer
European Journal of Clinical Pharmacology, 74, 4, pp. 465-471
Purpose Everolimus treatment is seriously hampered by its toxicity profile. As a relationship between everolimus exposure and effectiveness and toxicity has been established, early and ongoing concentration measurement can be key to individualize the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34fcd9ad4d61f32bb0698524ed7784e3
https://doi.org/10.1007/s00228-017-2394-0
https://doi.org/10.1007/s00228-017-2394-0
Autor:
Lotte M. Knapen
Cancer and type 2 diabetes mellitus are common conditions that pose a major threat to global health. Fortunately, better treatment options are becoming available for both disorders. However, the moment these new drugs become available - many uncertai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8370c6b21f2aa5b868cb030ad9d8d1
https://cris.maastrichtuniversity.nl/en/publications/ef3cce5a-f1d3-4ab9-8053-42ea4c015b34
https://cris.maastrichtuniversity.nl/en/publications/ef3cce5a-f1d3-4ab9-8053-42ea4c015b34
Autor:
Lotte M Knapen
Publikováno v:
OA Journal of Case Reports.
Crizotinib is an orally available tyrosine kinase inhibitor, approved for treatment of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement-positive non-small cell lung cancer (NSCLC). According to the product leaflet, crizotini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0d14cfe95bd2b7970449c9cdbf94a28
https://doi.org/10.33118/oaj.rep.2019.01.005
https://doi.org/10.33118/oaj.rep.2019.01.005
Autor:
Angela Colbers, Sander Croes, Frank de Vries, Rutger H. T. Koornstra, Bas van Vlijmen, David M. Burger, Winald R. Gerritsen, Lotte M. Knapen, Stein Schalkwijk, Johanna H M Driessen, Nielka P. van Erp
Publikováno v:
Targeted Oncology, 13(3), 363. Springer Paris
Targeted Oncology, 13, 363-370
Targeted Oncology, 13, 3, pp. 363-370
Targeted Oncology
Targeted Oncology, 13(3), 363-370. Springer, Cham
Targeted Oncology, 13, 363-370
Targeted Oncology, 13, 3, pp. 363-370
Targeted Oncology
Targeted Oncology, 13(3), 363-370. Springer, Cham
Background: The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is unknown.Objectives: To determine the association between progression of metastatic BRAF V600 mutated melanoma and (1) dose reduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b05d1cf905d061f6b835eff0a5c28814
https://dspace.library.uu.nl/handle/1874/368257
https://dspace.library.uu.nl/handle/1874/368257
Publikováno v:
OA Journal of Clinical Case Reports, 1:005. Omics Publishing Group
Crizotinib is an orally available tyrosine kinase inhibitor, approved for treatment of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement-positive non-small cell lung cancer (NSCLC). According to the product leaflet, crizotini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5913fc4dc59b9acc65914db8249e7b1f
https://doi.org/10.33118/oaj.clin.2019.01.005
https://doi.org/10.33118/oaj.clin.2019.01.005
Publikováno v:
Osteoporosis International, 28(8), 2429-2430. Springer-Verlag London Ltd.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98ef7d08edea5f410cd9c15b18d947bc
https://cris.maastrichtuniversity.nl/en/publications/712c50c7-4bf5-4396-9622-4ae21eb394a6
https://cris.maastrichtuniversity.nl/en/publications/712c50c7-4bf5-4396-9622-4ae21eb394a6
Autor:
Yolande C. Keulemans, Nielka P. van Erp, Sander Croes, Roy G.P.J. de Jong, Johanna H M Driessen, Marie L. De Bruin, Hubert G. M. Leufkens, Frank de Vries, Lotte M. Knapen
Publikováno v:
Diabetes, Obesity & Metabolism, 19, 3, pp. 401-411
Diabetes, Obesity and Metabolism, 19(3). Wiley-Blackwell
Diabetes, Obesity & Metabolism, 19, 401-411
Diabetes Obesity & Metabolism, 19(3), 401-411. Wiley
Publons
Diabetes, Obesity and Metabolism, 19(3). Wiley-Blackwell
Diabetes, Obesity & Metabolism, 19, 401-411
Diabetes Obesity & Metabolism, 19(3), 401-411. Wiley
Publons
Background Incretin-based therapies (Dipeptidyl Peptidase 4 inhibitors and Glucagon-Like Peptide-1 Receptor Agonists) are effective new agents for the treatment of Type 2 Diabetes Mellitus (T2DM). While incretin-based therapies have been associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772b4f8e68f8d4e396017e78664134f4
https://doi.org/10.1111/dom.12833
https://doi.org/10.1111/dom.12833
Autor:
Leo M L Stolk, Suzanne T. A. M. Dittrich, Frank de Vries, Marloes T Bazelier, Peter Vestergaard, Lotte M. Knapen, Ronald M.A. Henry, Cees Neef, Jakob Starup-Linde
Publikováno v:
Knapen, L M, Dittrich, S T A M, de Vries, F, Linde, J S, Vestergaard, P, Henry, R M A, Stolk, L M L, Neef, C & Bazelier, M T 2013, ' Use of biguanides and the risk of colorectal cancer : a register-based cohort study ', Current Drug Safety, vol. 8, no. 5, pp. 349-356 . https://doi.org/10.2174/15680266113136660068
Current Drug Safety, 8(5), 349-356. Bentham Science Publishers
Current Drug Safety, 8(5), 349-356. Bentham Science Publishers
Observational studies have shown conflicting results on the potential protecting effect of biguanide use with the risk of colorectal neoplasms. In addition, the cellular mechanism can either support or oppose biguanides influence on colorectal carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1af4874e557816bcc70c7216ac84b37
https://doi.org/10.2174/15680266113136660068
https://doi.org/10.2174/15680266113136660068
Autor:
Johanna H M Driessen, Y. C. Keulemans, Lotte M. Knapen, Marloes T Bazelier, J. van Dalem, F. de Vries, Sander Croes, Hubert G. M. Leufkens, M L De Bruin, N. P. van Erp, Cees Neef
Publikováno v:
Diabetes, Obesity & Metabolism, 18(3). Wiley-Blackwell
Diabetes, Obesity and Metabolism, 18(3), 258. Wiley-Blackwell
Diabetes, Obesity & Metabolism, 18, 3, pp. 258-65
Diabetes, Obesity & Metabolism, 18, 258-65
Diabetes Obesity & Metabolism, 18(3), 258-265. Wiley
Europe PubMed Central
Diabetes, Obesity and Metabolism, 18(3), 258. Wiley-Blackwell
Diabetes, Obesity & Metabolism, 18, 3, pp. 258-65
Diabetes, Obesity & Metabolism, 18, 258-65
Diabetes Obesity & Metabolism, 18(3), 258-265. Wiley
Europe PubMed Central
Item does not contain fulltext AIM: To investigate the association between the use of incretin agents and the risk of pancreatic cancer. METHODS: A retrospective population-based cohort study, using data from the Clinical Practice Research Datalink,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c44c5c7d11b02dd998d8e09b6b9bcf14
https://dspace.library.uu.nl/handle/1874/348396
https://dspace.library.uu.nl/handle/1874/348396